D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 97 Citations 63,732 666 World Ranking 4350 National Ranking 33

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Cancer
  • Surgery

Yi-Long Wu mostly deals with Lung cancer, Internal medicine, Oncology, Surgery and Chemotherapy. His Lung cancer research focuses on Gefitinib in particular. Internal medicine is a component of his Carboplatin, Hazard ratio, Pemetrexed, Carcinoma and Erlotinib studies.

His biological study spans a wide range of topics, including Phases of clinical research and Adenocarcinoma. The concepts of his Surgery study are interwoven with issues in Gastroenterology, Placebo, Clinical trial and Icotinib. Yi-Long Wu has researched Epidermal growth factor receptor in several fields, including Tyrosine kinase and Cancer research.

His most cited work include:

  • Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma (6022 citations)
  • Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study (2762 citations)
  • Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer (2444 citations)

What are the main themes of his work throughout his whole career to date?

Internal medicine, Lung cancer, Oncology, Cancer research and Chemotherapy are his primary areas of study. Internal medicine is often connected to Surgery in his work. His Lung cancer study integrates concerns from other disciplines, such as Cancer, Epidermal growth factor receptor and Adenocarcinoma.

His research in Epidermal growth factor receptor intersects with topics in Tyrosine kinase and Tyrosine-kinase inhibitor. His Oncology research incorporates elements of Carboplatin, Clinical endpoint, Clinical trial and Carcinoma. Yi-Long Wu combines subjects such as Mutation, KRAS, Anaplastic lymphoma kinase, Crizotinib and Immunotherapy with his study of Cancer research.

He most often published in these fields:

  • Internal medicine (60.82%)
  • Lung cancer (57.52%)
  • Oncology (52.16%)

What were the highlights of his more recent work (between 2019-2021)?

  • Internal medicine (60.82%)
  • Oncology (52.16%)
  • Lung cancer (57.52%)

In recent papers he was focusing on the following fields of study:

His primary areas of study are Internal medicine, Oncology, Lung cancer, Cancer research and Chemotherapy. His study in Gefitinib, Hazard ratio, Clinical endpoint, Lung and Tolerability falls within the category of Internal medicine. His Oncology study combines topics in areas such as Adjuvant therapy and Clinical trial, Phases of clinical research.

His Lung cancer research is multidisciplinary, incorporating elements of Cancer, Epidermal growth factor receptor, Adverse effect and Exon. Yi-Long Wu interconnects Tyrosine kinase, T cell, Anaplastic lymphoma kinase, Carcinoma and Crizotinib in the investigation of issues within Cancer research. His studies in Chemotherapy integrate themes in fields like Retrospective cohort study and Overall survival.

Between 2019 and 2021, his most popular works were:

  • COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. (181 citations)
  • Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA. (33 citations)
  • Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in EGFR / ALK wild-type advanced non-small cell lung cancer. (25 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Gene

His scientific interests lie mostly in Internal medicine, Oncology, Lung cancer, Cancer research and Chemotherapy. His studies deal with areas such as Lung, Cohort and Immunotherapy as well as Oncology. His study in Lung cancer focuses on Non small cell in particular.

His research on Cancer research also deals with topics like

  • Anaplastic lymphoma kinase, which have a strong connection to Crizotinib, Carcinoma and Tyrosine-kinase inhibitor,
  • Missense mutation, which have a strong connection to Nivolumab, Ipilimumab and Tyrosine. In his study, which falls under the umbrella issue of Chemotherapy, Carboplatin, Mutational status and First line therapy is strongly linked to Pembrolizumab. His study in Hazard ratio is interdisciplinary in nature, drawing from both Gastroenterology, Clinical endpoint and Response Evaluation Criteria in Solid Tumors.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Tony S. Mok;Yi Long Wu;Sumitra Thongprasert;Chih Hsin Yang.
The New England Journal of Medicine (2009)

8706 Citations

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

Alice T. Shaw;Dong Wan Kim;Kazuhiko Nakagawa;Takashi Seto.
The New England Journal of Medicine (2013)

3379 Citations

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Caicun Zhou;Yi Long Wu;Gongyan Chen;Jifeng Feng.
Lancet Oncology (2011)

2762 Citations

First-line crizotinib versus chemotherapy in ALK-positive lung cancer

Benjamin J. Solomon;Tony Shu-kam Mok;Dong Wan Kim;Yi Long Wu.
The New England Journal of Medicine (2014)

2710 Citations

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

Tony S. Mok;Yi Long Wu;Myung Ju Ahn;Marina C. Garassino.
The New England Journal of Medicine (2017)

1970 Citations

The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.

Peter Goldstraw;Kari Chansky;John Crowley;Ramon Rami-Porta.
Journal of Thoracic Oncology (2016)

1784 Citations

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

Edward S. Kim;Vera Hirsh;Tony Mok;Mark A. Socinski.
The Lancet (2008)

1682 Citations

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

Tudor Ciuleanu;Thomas Brodowicz;Christoph Zielinski;Joo Hang Kim.
The Lancet (2009)

1458 Citations

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

Tony S.K. Mok;Yi Long Wu;Iveta Kudaba;Dariusz M. Kowalski.
The Lancet (2019)

1175 Citations

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

Yi-Long Wu;Caicun Zhou;Cheng-Ping Hu;Jifeng Feng.
Lancet Oncology (2014)

1168 Citations

Editorial Boards

Annals of Oncology
(Impact Factor: 51.769)

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Yi-Long Wu

Caicun Zhou

Caicun Zhou

Tongji University

Publications: 155

Rafael Rosell

Rafael Rosell

Autonomous University of Barcelona

Publications: 143

Myung-Ju Ahn

Myung-Ju Ahn

Samsung Medical Center

Publications: 143

Pasi A. Jänne

Pasi A. Jänne

Harvard University

Publications: 142

Benjamin Besse

Benjamin Besse

Institut Gustave Roussy

Publications: 133

James Chih-Hsin Yang

James Chih-Hsin Yang

National Cancer Institute

Publications: 129

Tony Mok

Tony Mok

Chinese University of Hong Kong

Publications: 128

Alice T. Shaw

Alice T. Shaw

Harvard University

Publications: 120

Kazuhiko Nakagawa

Kazuhiko Nakagawa

Kindai University

Publications: 119

Ming-Sound Tsao

Ming-Sound Tsao

Princess Margaret Cancer Centre

Publications: 115

Lecia V. Sequist

Lecia V. Sequist

Harvard University

Publications: 114

Keunchil Park

Keunchil Park

Samsung Medical Center

Publications: 109

Silvia Novello

Silvia Novello

University of Turin

Publications: 109

Frances A. Shepherd

Frances A. Shepherd

Princess Margaret Cancer Centre

Publications: 107

Dong-Wan Kim

Dong-Wan Kim

Seoul National University Hospital

Publications: 106

Natasha B. Leighl

Natasha B. Leighl

Princess Margaret Cancer Centre

Publications: 101

Trending Scientists

Han Vinck

Han Vinck

University of Duisburg-Essen

Bernard Henri Fleury

Bernard Henri Fleury

Aalborg University

Pavel Martásek

Pavel Martásek

Charles University

Frank R. N. Gurd

Frank R. N. Gurd

Indiana University

Jiefang Li

Jiefang Li

Virginia Tech

Daniel Moura de Aguiar

Daniel Moura de Aguiar

Universidade Federal de Mato Grosso

Curtis J. Omiecinski

Curtis J. Omiecinski

Pennsylvania State University

Brett J. Baker

Brett J. Baker

The University of Texas at Austin

Thomas C. Hart

Thomas C. Hart

National Institutes of Health

Lee-Yuan Liu-Chen

Lee-Yuan Liu-Chen

Temple University

Paul Allen

Paul Allen

University of Roehampton

Werner Paulus

Werner Paulus

University of Münster

Robert B. Zipursky

Robert B. Zipursky

University of Toronto

Jeroen Smits

Jeroen Smits

Radboud University Nijmegen

Ravi Dhar

Ravi Dhar

Yale University

Something went wrong. Please try again later.